Supplementary file

Supplementary Fig. S1. Proportion of patients achieving a meaningful improvement for work productivity loss (A) and activity impairment (B) at Week 24 in integrated SPIRIT-P1/SPIRIT-P2 analysis set by baseline CPDAI severity. CPDAI severity was defined as peripheral arthritis domain score ≥3 and total score ≥8.

*p<0.001, *p<0.05 versus placebo based on Fisher’s test. CPDAI: Composite Psoriatic Disease Activity Index; IXEQ2W: ixekizumab 80 mg every 2 weeks; IXEQ4W: ixekizumab 80 mg once every 4 weeks; MCID: minimal clinically important difference; Ns: number of patients in each subgroup; NRI: non-responder imputation.